<DOC>
	<DOC>NCT02405442</DOC>
	<brief_summary>This study will primarily evaluate the safety and efficacy of GS-5745 in adults with active Crohn's disease. The study will consist of a Blinded Treatment Period of 8 weeks followed by an Open Label Extension. Participants who complete the Blinded Treatment Period will be eligible to enroll in the optional Open Label Extension for an additional 44 weeks. Participants who complete Week 52 assessments will be eligible to enter the Extended Treatment Phase to continue treatment with GS-5745 for an additional 156 weeks.</brief_summary>
	<brief_title>Safety and Efficacy of GS-5745 in Participants With Moderately to Severely Active Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Key Ability to provide a written informed consent Females of childbearing potential must have a negative pregnancy test at screening and baseline Documented diagnosis of Crohn's disease with a minimum disease duration of 6 months with involvement of the ileum and/or colon at a minimum Moderately to severely active Crohn's disease as defined by a CDAI total score between 220450 (inclusive) AND with evidence of active disease as measured by ileocolonoscopy Within the previous 5 years, demonstrated an inadequate clinical response or intolerance of at least one of the following agents: Corticosteroids: Immunomodulators: tumor necrosis factoralpha (TNFÎ±) Antagonists: Vedolizumab: May be receiving the following drugs: Oral 5aminosalicylate (5ASA) Oral corticosteroid therapy Antidiarrheals for chronic diarrhea Azathioprine or 6mercaptopurine (6MP) or methotrexate Antibiotics for the treatment of Crohn's Disease Able to comply with the dosing instructions for study drug and able to comply with the study visits and requirements Key Evidence of abscess at screening Extensive colonic resection (subtotal or total colectomy) or history of &gt; 2 small bowel resections Ileostomy, colostomy, or symptomatic stenosis of the intestine Current use of oral corticosteroids at a dose equivalent to &gt; 30 mg/day of prednisone Ulcerative colitis or indeterminate colitis Short bowel syndrome Stool sample positive for Clostridium difficile (C. difficile) toxin, E. coli, Salmonella, Shigella, Campylobacter or Yersinia Treatment with any monoclonal antibody within 4 weeks of screening History or evidence of colonic mucosal dysplasia HIV, hepatitis B, hepatitis C, or tuberculosis (TB) infection Participated in a clinical study with an investigational drug or biologic within the last 30 days Any chronic medical condition (including, but not limited to, cardiac or pulmonary disease) that, in the opinion of the investigator, would make the individual unsuitable for the study or would prevent compliance with the study protocol NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>